Analysts split on Amazon RxPass's impact on GoodRx Holdings

Go back to Analysts split on Amazon RxPass's impact on GoodRx Holdings

Citi Says Amazon (AMZN) RxPass 'Presents Credible Threat' to GoodRx Holdings Inc. (GDRX)

January 24, 2023 1:23 PM EST

Citi analyst Daniel Grosslight reiterated a Buy rating and $7.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX).

The analyst comments "AMZN announced today it is rolling out a new product, RXPass, which provides AMZNs 150-175M US Prime members with unlimited... More